A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS

S. N. Scelsa, D. J.L. MacGowan, H. Mitsumoto, T. Imperato, A. J. LeValley, M. H. Liu, M. DelBene, M. Y. Kim

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

There is some evidence of retroviral infection in ALS. A randomized, double-blind, placebo-controlled trial of indinavir in ALS was performed to assess safety and efficacy trends. Nephrolithiasis and gastrointestinal side effects were frequent with indinavir treatment. Group differences in the rate of decline were not significant between the groups for the ALS Functional Rating Scale (p = 0.36) or for the secondary variables. The toxicity and negative efficacy trends discourage further indinavir trials in ALS.

Original languageEnglish (US)
Pages (from-to)1298-1300
Number of pages3
JournalNeurology
Volume64
Issue number7
DOIs
StatePublished - Apr 12 2005

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS'. Together they form a unique fingerprint.

Cite this